Skip to content
Screener

Viking Therapeutics VKTX Other income, net (Note 6)

Other income, net (Note 6) at other companies

Pfizer logo
PfizerPFE
$3.72B+603%
Gyre Therapeutics, Inc. logo
Gyre Therapeutics, Inc.GYRE
-$943K-93.2%
Madrigal Pharmaceuticals, Inc. logo
Madrigal Pharmaceuticals, Inc.MDGL
-$795K-1,793%
Altimmune logo
AltimmuneALT
-$152K-1,113%
Wave Life Sciences logo
Wave Life SciencesWVE
-$275K-235%
Amylyx Pharmaceuticals, Inc. logo
Amylyx Pharmaceuticals, Inc.AMLX
-$53K+90.3%

Other financials

Income statement

See full
Revenue-
Operating income-$164.1M-196%
Net income-$158.3M-247%
EPS (diluted)-$1.37-234%

Balance sheet

See full
Cash & equivalents$118.1M+211%
Total debt$137.0K-87.8%
Total equity$501.9M-40.7%
Total assets$608.2M-29.8%

Cash flow

See full
Operating cash flow-$114.0M-118%

Valuation

See full
Market cap$3.88B+8.4%

Returns & leverage

See full
Return on equity-70%-94.5pp
Debt / equity0.0×
Current ratio5.7×-38.5×

Where this comes from

Reported directly by Viking Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:OtherNonoperatingIncomeExpense.

The source filing: Viking Therapeutics’s 10-Q, filed April 30, 2026.

Filed
Apr 29, 2026, 9:50 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001193125-26-193315
RevenuesThree Months Ended March 31, 2026 / —Three Months Ended March 31, 2025 / —
Other income (expense):
Amortization of financing costs(24)
Interest income, net5,8009,864
Total other income, net5,8009,840
Net loss(158,325)(45,629)
Other comprehensive loss, net of tax:
Unrealized (loss) gain on securities(1,250)563
Foreign currency translation gain169

Item 1. Financial Statements

FAQ

What is Viking Therapeutics's other income, net (note 6)?
Viking Therapeutics (VKTX) reported other income, net (note 6) of $5.8M in Q1 2026.
How has Viking Therapeutics's other income, net (note 6) changed year-over-year?
Viking Therapeutics's other income, net (note 6) decreased by 41.1% year-over-year, from $9.84M to $5.8M.
What is the long-term trend for Viking Therapeutics's other income, net (note 6)?
Over 4 years (2021 to 2025), Viking Therapeutics's other income, net (note 6) has grown at a 164.2% compound annual growth rate (CAGR), from $692K to $33.7M.
What does other income, net (note 6) mean?
This captures miscellaneous financial items that fall outside the scope of core operating activities, such as foreign exchange gains or losses, minor investment income, or non-recurring legal settlements. It serves as a catch-all for peripheral financial events that do not stem from the primary business operations. Investors monitor this to isolate core earnings from transient or incidental financial fluctuations.

Ask your AI about Viking Therapeutics's other income, net (note 6).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude